HUP0302416A2 - Tisztított hepatitis-C vírusmembrán-proteinek diagnosztikai és terápiás célú alkalmazása - Google Patents
Tisztított hepatitis-C vírusmembrán-proteinek diagnosztikai és terápiás célú alkalmazásaInfo
- Publication number
- HUP0302416A2 HUP0302416A2 HU0302416A HUP0302416A HUP0302416A2 HU P0302416 A2 HUP0302416 A2 HU P0302416A2 HU 0302416 A HU0302416 A HU 0302416A HU P0302416 A HUP0302416 A HU P0302416A HU P0302416 A2 HUP0302416 A2 HU P0302416A2
- Authority
- HU
- Hungary
- Prior art keywords
- diagnostic
- hcv
- hepatitis
- virus
- proteins
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title abstract 7
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 108010003533 Viral Envelope Proteins Proteins 0.000 title 1
- 238000012544 monitoring process Methods 0.000 abstract 3
- 108010065667 Viral Matrix Proteins Proteins 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 2
- 238000000746 purification Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 206010008909 Chronic Hepatitis Diseases 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgyát rekombináns proteinek termeltetése, tisztítása,szintetikus peptidek, hepatitis-C-vírus (HCV) okozta fertőzésdiagnosztizálása, HCV-fertőzés megelőzésszerű kezelése és krónikushepatitistől szenvedő személy kezelésének klinikai hatékonyságaprognosztizálása/monitorozása vagy természetes betegségprognosztizálása/monitorozása képezi. Közelebbről, a találmány tárgyáteljárások képezik hepatitis-C-vírus (HCV), vírusmembrán- (<envelope<)proteinjeinek tisztítására; a találmány szerinti eljárásokalkalmazásával tisztított HCV-vírusmembrán-proteinek diagnosztikai,profilaktikus vagy terápiás alkalmazása; monomer vagy specifikusoligomer E1 és/vagy E2 és/vagy E1/E2 vírusmembrán-proteinekalkalmazása betegség monitorozására és/vagy diagnosztizálására és/vagygyógykezelésére. Szintén a találmány tárgyát képezik az E1 és/vagy E2vírusmembrán-proteinek epitópjai, az ellenük irányuló monoklonálisantitestek, továbbá az antitestek diagnosztikai, profilaktikus vagygyógykezelési célú alkalmazása. Ó
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26066901P | 2001-01-11 | 2001-01-11 | |
| US31576801P | 2001-08-30 | 2001-08-30 | |
| PCT/EP2002/000219 WO2002055548A2 (en) | 2001-01-11 | 2002-01-11 | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0302416A2 true HUP0302416A2 (hu) | 2003-10-28 |
Family
ID=26948130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0302416A HUP0302416A2 (hu) | 2001-01-11 | 2002-01-11 | Tisztított hepatitis-C vírusmembrán-proteinek diagnosztikai és terápiás célú alkalmazása |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1463753A2 (hu) |
| KR (1) | KR20020089371A (hu) |
| CN (1) | CN1547588A (hu) |
| AR (1) | AR032240A1 (hu) |
| AU (1) | AU2002238502B2 (hu) |
| BR (1) | BR0203518A (hu) |
| CA (1) | CA2400643A1 (hu) |
| CZ (1) | CZ20032164A3 (hu) |
| HU (1) | HUP0302416A2 (hu) |
| IL (1) | IL151033A0 (hu) |
| MX (1) | MXPA02008886A (hu) |
| NO (1) | NO20024325L (hu) |
| PL (1) | PL363175A1 (hu) |
| RU (1) | RU2313363C2 (hu) |
| TR (1) | TR200202169T1 (hu) |
| WO (1) | WO2002055548A2 (hu) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002085932A2 (en) | 2001-04-24 | 2002-10-31 | Innogenetics N.V. | Constructs and methods for expression of recombinant hcv envelope proteins |
| AU2003283365A1 (en) * | 2002-11-08 | 2004-06-07 | Innogenetics N.V. | HCV vaccine compositions comprising E1 and NS3 peptides |
| EP1561470A1 (en) * | 2003-06-20 | 2005-08-10 | Innogenetics N.V. | HCV vaccines comprising the envelope-1 (E1) protein or the corresponding DNA and at least one antiviral agent |
| CN102659922B (zh) * | 2003-09-22 | 2013-11-06 | 株式会社绿多肽 | 来源于c型肝炎病毒的肽 |
| CN100365124C (zh) * | 2005-10-27 | 2008-01-30 | 云南大学 | 一段丙型肝炎病毒特异性cDNA序列的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2174957T5 (es) * | 1994-07-29 | 2006-12-16 | Innogenetics N.V. | Proteinas purificadas de envoltura de virus de la hepatitis c para uso diagnostico y terapeutico. |
-
2002
- 2002-01-11 WO PCT/EP2002/000219 patent/WO2002055548A2/en active IP Right Grant
- 2002-01-11 TR TR2002/02169T patent/TR200202169T1/xx unknown
- 2002-01-11 AU AU2002238502A patent/AU2002238502B2/en not_active Ceased
- 2002-01-11 CN CNA028006097A patent/CN1547588A/zh active Pending
- 2002-01-11 CA CA002400643A patent/CA2400643A1/en not_active Abandoned
- 2002-01-11 MX MXPA02008886A patent/MXPA02008886A/es active IP Right Grant
- 2002-01-11 CZ CZ20032164A patent/CZ20032164A3/cs unknown
- 2002-01-11 KR KR1020027011431A patent/KR20020089371A/ko active IP Right Grant
- 2002-01-11 RU RU2002121632/15A patent/RU2313363C2/ru not_active IP Right Cessation
- 2002-01-11 PL PL02363175A patent/PL363175A1/xx unknown
- 2002-01-11 IL IL15103302A patent/IL151033A0/xx unknown
- 2002-01-11 EP EP02704649A patent/EP1463753A2/en not_active Withdrawn
- 2002-01-11 BR BR0203518-9A patent/BR0203518A/pt not_active Withdrawn
- 2002-01-11 HU HU0302416A patent/HUP0302416A2/hu unknown
- 2002-01-14 AR ARP020100104A patent/AR032240A1/es unknown
- 2002-09-10 NO NO20024325A patent/NO20024325L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2400643A1 (en) | 2002-07-18 |
| AU2002238502A1 (en) | 2002-07-24 |
| NO20024325L (no) | 2002-11-11 |
| IL151033A0 (en) | 2003-04-10 |
| CZ20032164A3 (cs) | 2003-10-15 |
| RU2313363C2 (ru) | 2007-12-27 |
| WO2002055548A8 (en) | 2002-10-31 |
| EP1463753A2 (en) | 2004-10-06 |
| AU2002238502B2 (en) | 2007-09-06 |
| WO2002055548A2 (en) | 2002-07-18 |
| AR032240A1 (es) | 2003-10-29 |
| WO2002055548A3 (en) | 2004-08-05 |
| MXPA02008886A (es) | 2003-04-25 |
| CN1547588A (zh) | 2004-11-17 |
| KR20020089371A (ko) | 2002-11-29 |
| TR200202169T1 (tr) | 2004-06-21 |
| BR0203518A (pt) | 2002-12-17 |
| AU2002238502B9 (en) | 2002-07-24 |
| PL363175A1 (en) | 2004-11-15 |
| RU2002121632A (ru) | 2004-03-20 |
| NO20024325D0 (no) | 2002-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Taniguchi et al. | A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: implication for an escape from antibody | |
| ES2174957T5 (es) | Proteinas purificadas de envoltura de virus de la hepatitis c para uso diagnostico y terapeutico. | |
| DE602004025668D1 (de) | Methoden der verhinderung und behandlung der alzheimer'schen krankheit | |
| HUP0102478A2 (hu) | A HCV-burokfehérjék által alkotott részecskék alkalmazása vakcinázásban | |
| GILLJAM | Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses | |
| DE3588254D1 (de) | Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen | |
| DE60142683D1 (de) | Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen | |
| RU2008130893A (ru) | Адипогенные аденовирусы как биомаркеры заболеваний | |
| JP2003501661A (ja) | Ｎｓ１糖タンパク質を用いるフラビウイルスの早期検出 | |
| AR035867A1 (es) | Una particula semejante a un virus hcv formada por una proteina de envoltura de hcv, un metodo para formar dicha particula, un medicamento que la contiene, una vacuna, un metodo de deteccion, un kit de diagnostico, el uso de cepas de hansenula o saccharomyces para la expresion de una proteina hcv, e | |
| EA201170353A1 (ru) | Антитела против гепатита с и их применение | |
| WO2004085633A8 (en) | A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof | |
| HUP9801334A2 (hu) | A 18-as típusú humán papillomavírust kódoló DNS | |
| DE69132762D1 (de) | Menschliche, monoklonale Antikörper gegen das transmembrane Glycoprotein (gp41) des HIV-1, und verwandte Peptide | |
| ATE457353T1 (de) | Virales latentphasen-interleukin-10-(vii-10) und verwendungen davon | |
| HUP0302416A2 (hu) | Tisztított hepatitis-C vírusmembrán-proteinek diagnosztikai és terápiás célú alkalmazása | |
| TW200513260A (en) | Hepatitis C virus derived peptides | |
| CN113248608B (zh) | 一种基孔肯雅病毒e2蛋白兔单克隆抗体及其用途 | |
| WO1997004099A3 (de) | Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen | |
| HUP0204176A2 (hu) | PRRSV rekombináns virulencia gyengítése | |
| ES2166752T3 (es) | Asociacion entre un retrovirus relacionado con el virus de inmunodeficiencia humana y el sindrome de sjogren. | |
| HUP0003511A2 (hu) | Hepatitisz-B-vírus polipeptidek | |
| JP2001522599A (ja) | 診断用及びワクチン用、ｃ型肝炎ウイルスエンベロープタンパク質由来マルチマーペプチド | |
| WO1999009177A3 (de) | Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen | |
| WO1998023752A3 (de) | Papillomviren, mittel zu deren nachweis sowie zur therapie von durch sie verursachten erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB9A | Succession in title |
Owner name: GENIMMUNE N.V., BE Free format text: FORMER OWNER(S): INNOGENETICS N.V., BE |
|
| FD9A | Lapse of provisional protection due to non-payment of fees |